-

Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences.

  • Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm E.T.
  • Piper Sandler 36th Annual Healthcare Conference: Presentation on December 3, 2024, at 4:10 pm E.T.

About Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.

For more information, visit us on LinkedIn and at abcuro.com.

Contacts

Matthew DeYoung
Investor Relations and Media
Argot Partners
abcuro@argotpartners.com

Industry:

Abcuro, Inc.

Release Versions
English

Contacts

Matthew DeYoung
Investor Relations and Media
Argot Partners
abcuro@argotpartners.com

More News From Abcuro, Inc.

Abcuro Appoints Courtney Cupples as Chief Commercial Officer

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Courtney Cupples as Chief Commercial Officer (CCO). Ms. Cupples brings more than 25 years of global commercial leadership and rare disease product launch experience. “We are excited to welcome Courtney to Abcuro as a key member of the leadership team as we...

Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the Company will present safety, pharmacokinetic, and pharmacodynamic data from the Phase 1 clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 5-9...

Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the closing of a $200 million Series C financing led by New Enterprise Associates (NEA) with Foresite Capital joining the round and participation of existing investors including RA Capital Management, Bain Capital Life Sciences, Redmile Group, Samsara BioCapital, Sanofi Ventu...
Back to Newsroom